Phase IIb Trial of IPP-201101

Immupharma PLC
26 February 2008


For Immediate Release                                  26 February 2008




                                 ImmuPharma PLC


         First Lupus patients dosed with IPP-201101 in phase IIb study


ImmuPharma PLC (LSE:IMM), ('ImmuPharma' or the 'Company'), the specialist drug
discovery and development company, announces today that the first patients have
been dosed in its phase IIb trial of IPP-201101 for the treatment of Systemic
Lupus Erythematosus. Assuming continued satisfactory patient recruitment with
the trial, headline efficacy data are expected in the summer of 2008 as
previously indicated.


The phase IIb clinical study is designed to evaluate the efficacy and safety of
IPP-201101 in patients with Systemic Lupus Erythematosus (SLE). The primary
objective of the study is to assess the effect of subcutaneous IPP-201101 on the
signs and symptoms of disease activity in subjects with active SLE, over a
12-week treatment period, compared to placebo.


The phase IIb study has been designed as a multicenter, randomized,
double-blind, placebo-controlled dose-ranging study to evaluate the safety,
tolerability and efficacy of two doses of subcutaneous IPP-201101 plus standard
of care, versus placebo plus standard of care in Subjects with SLE. The first
patients have been dosed in Buenos Aires, Argentina. The study is being
conducted in 7 countries in 43 sites, across Europe and Latin America, and is
expected to enrol up to 204 patients.


Dr Robert Zimmer, MD, PhD, President and Chief Scientific Officer of ImmuPharma
said: 'We are delighted to announce further progress in IPP-2011101 development
while we believe more than ever that IPP-201101 will significantly improve
treatment options and the quality of life for SLE patients. IPP-201101
represents a novel strategy for the treatment of SLE that has demonstrated
encouraging potential in initial clinical studies. We are optimistic that the
study will proceed well in the coming months and we look forward to reporting on
our progress later this year.'





For further information please contact:

ImmuPharma PLC:
Dimitri Dimitriou, Chief Executive                     [phone]
Officer
Dr Robert Zimmer, President & Chief                   + 33 389 32 76 50
Scientific Officer
Richard Warr, Chairman                                 [phone]

Buchanan Communications                               + 44 20 7466 5000
Lisa Baderoon
Rebecca Skye Dietrich

Panmure Gordon & Co
Andrew Burnett                                         [phone]




For company information, visit www.immupharma.com



Notes to Editors:


About ImmuPharma


ImmuPharma PLC is a specialist drug discovery and development company (LSE:IMM).
It has research operations in France (ImmuPharma (France) SA) and Switzerland
(ImmuPharma AG). ImmuPharma is dedicated to the development of novel drugs,
largely based on peptide therapeutics, to treat serious medical conditions such
as autoimmune diseases characterised by:


*                blockbuster potential in niche markets


*                low promotional costs in few specialised physicians and centres
and


*                lower risk of drug development and lower development costs


ImmuPharma is currently developing drug candidates for five different medical
conditions, each of which would represent a significant breakthrough in its
field. The lead product candidate i targets Lupus, a disease for which there is
currently no cure or specific treatment. The other four address cancer, moderate
to severe pain (such as that experienced by cancer sufferers and post-operative
patients), MRSA and severe hospital-acquired resistant infections and
inflammation / allergic disorders.


All product candidates have significant sales potential as well as low marketing
costs and a relatively low risk of development failure. One or more have the
potential to be fast-tracked by the US Food and Drug Administration according to
'Guidance for Industry: Fast Track Drug Development Programs - Designation,
Development and Application Review' issued July 2004 and could therefore obtain
their market authorization by 2010.


Key to the potential success of ImmuPharma is its unique collaborative agreement
with Centre National de la Recherche Scientifique, France's scientific research
institution. This agreement grants ImmuPharma worldwide exclusive rights to
exploit certain key discoveries.


In addition to its three leading drug candidates, ImmuPharma has a drug
development pipeline using its rights to a virtual chemical library of hundreds
of thousands of molecules as well as an innovative technology for converting
peptides to drug candidates.


ImmuPharma has the option to commercialise its assets itself or to license them
to other pharmaceutical companies at an earlier stage.







                      This information is provided by RNS
            The company news service from the London Stock Exchange